Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Ge...( NEW BRUNSWICK N.J. May 27 /-...)

NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT) announced today that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco's multiple myeloma studies at the 12th Annual Meeting of the American Society of Gene Therapy, which is being held at the San Diego Convention Center in San Diego, CA, from Wednesday, May 27th through to Saturday, May 30th, 2009. Mr. Dondero will be presenting in the afternoon session on Thursday, May 28th.

The American Society of Gene Therapy (ASGT) is a non-profit medical and professional organization that represents researchers and scientists devoted to the discovery of new gene and cell therapies. ASGT was established in 1996, and with more than 2,000 members in the United States and worldwide, ASGT is the largest association of individuals involved in gene and cell therapeutics.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases. Senesco takes its name from the scientific term for the aging of plant cells: senescence. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress. The Company believes that its technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Sen
'/>"/>